Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups

Therapeutic Drug Monitoring

Volumn 22, Issue 5, 2000, Pages 510-516

  Britzi, Malka ^a,b   Bialer, Meir ^b   Arcavi, Lidia ^b   Shachbari, Asmi ^b   Kapitulnik, Jaime ^c   Soback, Stefan ^a  

^a KIMRON VETERINARY INSTITUTE   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

CYP2C19; CYP2D6; Gas chromatography mass spectrometry; Genetic polymorphism; High performance liquid chromatography; Stereoselective pharmacokinetics

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN; DEXTRORPHAN; ISOENZYME; MEPHENYTOIN;

ARTICLE; DRUG METABOLISM; ETHNIC GROUP; GAS CHROMATOGRAPHY; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMIGRANT; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTICONVULSANTS; ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISRAEL; MALE; MEPHENYTOIN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENOTYPE; POLYMORPHISM, GENETIC; REFERENCE VALUES;

EID: 0033802124     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200010000-00002     Document Type: Article

References (19)

1. Molecular mechanisms of genetic polymorphisms of drug metabolism
2. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans
3. Use of probe drugs as predictors of drug metabolism in humans
4. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota
5. Clinical importance of genetic polymorphism of drug oxidation
6. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
7. High-performance liquid chromatography determination of urinary 4-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C 19, in humans
8. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects
9. Geographical/interracial differences in polymorphic drug oxidation
10. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man
11. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation
12. Extensive oxidative metabolism of dextromethorphan in patients with almirine neuropathy
13. Antidepressant drug interactions and the cytochrome P450 system
14. Drug interactions and the cytochrome P450 system
15. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography
16. Limitation to the use of the urinary S/R-mephenytoin ratio in pharmacogenetic studies
17. Oxidative polymorphism of dextromethorphan in a Burundi population
18. Frequent distribution of ultrarapid metabolizers of debrisoquin in an Ethiopian population carrying duplicate and multiduplicated functional CYP2D6 alleles
19. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population